The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor–Associated Genitourinary Infections
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280241227973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Anthony Gerber und 3 weiteren Autor:innen. Beteiligte Einrichtung: New York City Health + Hospital/Bellevue, New York City, NY, US. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glycemic Control, Glycated Hemoglobin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Patients with type 2 diabetes (T2D) are at an increased risk of genital urinary (GU) infections, with the risk increasing with higher A1Cs. Given the broad adoption of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in patients with T2D, both providers and patients need to be aware of common adverse effects associated with these medications, specifically GU infections. However trials involving SGLT2is looked at patients with an average A1C of less than 9%, and thus, the incidence of GU infections may not truly reflect the general diabetic population.
Objective
The purpose of this study is to assess the association between GU infections in patients started on SGLT2is and A1C levels.
Methods
A retrospective study was conducted on patients seen in an adult, primary care clinic, at New York City Health and Hospitals, South Brooklyn Health. Men and nonpregnant, nonlactating women >18 years old with a diagnosis of T2D who were initiated on an SGLT2i between January 2018 and January 2023 were included in the analysis. The primary endpoint is to compare the risk of GU infections in patients with T2D who were started on SGLT2is, regardless of dose, with hemoglobin A1C of >9% to those with hemoglobin A1C 9% compared with those with an A1C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- New York City Health + Hospital/Bellevue, New York City, NY, US.
- New York City Health + Hospital/South Brooklyn Health, Brooklyn, NY, USA.
- New York Institute of Technology, Westbury, NY, USA.
ORCID-Profile: Anthony Gerber
Zitieren
APA
Gerber, A., Rupp, V., Ryabenkova, N., & Mikhelzon, N. (2024). The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor–Associated Genitourinary Infections. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241227973
Vancouver
Gerber A, Rupp V, Ryabenkova N, Mikhelzon N. The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor–Associated Genitourinary Infections. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280241227973
BibTeX
@article{Gerber2024,
author = {Gerber, Anthony and Rupp, Victoria and Ryabenkova, Natalia and Mikhelzon, Nataliya},
title = {The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor–Associated Genitourinary Infections},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280241227973}
}
EUVIMED